{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:02:21Z","timestamp":1789794141790,"version":"4.0.1"},"reference-count":77,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["R01 CA251198"],"award-info":[{"award-number":["R01 CA251198"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>High-grade serous carcinoma (HGSC) of tubo-ovarian origin is an aggressive malignancy in need of new treatment options. At the molecular level, HGSC is characterized by genomic instability, including nearly universal TP53 mutations, copy number alterations, and chromothripsis, which elevate replication stress. These fundamental alterations result in tumor cell dependence on the G2\/M checkpoint for survival, thus revealing this checkpoint as a potential therapeutic target. In this review, we discuss the normal cell cycle progression and checkpoints as well as the regulation of DNA replication, and we consider how replication stress in HGSC leads to a dependence on the G2\/M checkpoint. We then present information on the current state of targeted therapy development for HGSC including clinical trials and the role of biomarkers in optimal patient selection. Thus, targeting the G2\/M checkpoint is driven by sound molecular rationale and may yield clinical benefit in patients with HGSC, but will likely require careful patient selection and consideration of treatment toxicities.<\/jats:p>","DOI":"10.3390\/genes17091135","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:03:17Z","timestamp":1789632197000},"page":"1135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["G2\/M Checkpoint Dependency in High-Grade Serous Tubo-Ovarian Carcinoma: Mechanisms and Therapeutic Implications"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6180-8008","authenticated-orcid":false,"given":"Zhiyu","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7833-1967","authenticated-orcid":false,"given":"Karen","family":"McLean","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA"},{"name":"Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"K\u00f6bel, M., and Kang, E.Y. (2022). The Evolution of Ovarian Carcinoma Subclassification. Cancers, 14.","DOI":"10.3390\/cancers14020416"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1038\/s41598-022-20769-5","article-title":"CDK4\/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1\/S transition","volume":"12","author":"Kim","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1367-5931(00)00134-4","article-title":"Mechanisms of DNA replication","volume":"4","author":"Davey","year":"2000","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"a000737","DOI":"10.1101\/cshperspect.a000737","article-title":"Organization of DNA replication","volume":"2","author":"Chagin","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.molcel.2022.05.004","article-title":"Hallmarks of DNA replication stress","volume":"82","author":"Saxena","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.14791\/btrt.2025.0017","article-title":"Therapeutic Targeting of DNA Damage Response Pathways in TP53- and ATM-Mutated Tumors","volume":"13","author":"Shim","year":"2025","journal-title":"Brain Tumor Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Timmerman, D.M., Remmers, T.L., Hillenius, S., and Looijenga, L.H.J. (2021). Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells\u2014Relevance for Understanding (Germ Cell) Tumorigenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105377"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.18632\/oncotarget.3103","article-title":"p53 activates G1 checkpoint following DNA damage by doxorubicin during transient mitotic arrest","volume":"6","author":"Hyun","year":"2015","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: At least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e37868","DOI":"10.7554\/eLife.37868","article-title":"Loss of p53 suppresses replication-stress-induced DNA breakage in G1\/S checkpoint deficient cells","volume":"7","author":"Benedict","year":"2018","journal-title":"eLife"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"Chowdhury","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1385\/1-59259-788-2:051","article-title":"Analyzing the G2\/M checkpoint","volume":"Volume 280","author":"Stark","year":"2004","journal-title":"Checkpoint Controls and Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gorecki, L., Andrs, M., and Korabecny, J. (2021). Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. Cancers, 13.","DOI":"10.3390\/cancers13040795"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature25507","article-title":"Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress","volume":"555","author":"Macheret","year":"2018","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e20190138","DOI":"10.1590\/1678-4685-gmb-2019-0138","article-title":"DNA replication stress: Oncogenes in the spotlight","volume":"43","author":"Primo","year":"2020","journal-title":"Genet. Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","article-title":"Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas","volume":"15","author":"Etemadmoghadam","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gorski, J.W., Ueland, F.R., and Kolesar, J.M. (2020). CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. Diagnostics, 10.","DOI":"10.3390\/diagnostics10050279"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Fagundes, R., and Teixeira, L.K. (2021). Cyclin E\/CDK2: DNA Replication, Replication Stress and Genomic Instability. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.774845"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1038\/s41467-025-58183-w","article-title":"Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","article-title":"Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer","volume":"166","author":"Zhang","year":"2016","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Xie, T., Dickson, K.A., Yee, C., Ma, Y., Ford, C.E., Bowden, N.A., and Marsh, D.J. (2022). Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. Cancers, 14.","DOI":"10.3390\/cancers14194621"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Callen","year":"2016","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liptay, M., Barbosa, J.S., and Rottenberg, S. (2020). Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00670"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited Mutations in Women With Ovarian Carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13073-018-0590-x","article-title":"Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors","volume":"10","author":"Yang","year":"2018","journal-title":"Genome Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2426909122","DOI":"10.1073\/pnas.2426909122","article-title":"Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma","volume":"122","author":"Tien","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole\u2013genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9333284","DOI":"10.1155\/humu\/9333284","article-title":"Integrative Genomic and Functional Analysis Reveals NF1 Loss as a Modifier of DNA Damage and Replication Stress Responses in Ovarian Cancer","volume":"2026","author":"He","year":"2026","journal-title":"Hum. Mutat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10689-020-00184-3","article-title":"Biallelic NF1 inactivation in high grade serous ovarian cancers from patients with neurofibromatosis type 1","volume":"19","author":"Courtney","year":"2020","journal-title":"Fam. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100004","DOI":"10.1016\/j.xcrm.2020.100004","article-title":"Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability","volume":"1","author":"McDermott","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.molcel.2012.03.001","article-title":"Preventing Replication Stress to Maintain Genome Stability: Resolving Conflicts between Replication and Transcription","volume":"45","author":"Bermejo","year":"2012","journal-title":"Mol. Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.acc.2014.12.003","article-title":"Chapter Three\u2014Cancer Therapy and Replication Stress: Forks on the Road to Perdition","volume":"Volume 69","author":"Makowski","year":"2015","journal-title":"Advances in Clinical Chemistry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1101\/gad.288142.116","article-title":"Replication fork instability and the consequences of fork collisions from rereplication","volume":"30","author":"Alexander","year":"2016","journal-title":"Genes Dev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2217\/epi-2023-0379","article-title":"Bridging the gap: R-loop mediated genomic instability and its implications in neurological diseases","volume":"16","author":"Westover","year":"2024","journal-title":"Epigenomics"},{"key":"ref_41","first-page":"6","article-title":"R-loops in hepatocellular carcinoma: Bridging genomic instability and therapeutic opportunity (Review)","volume":"33","author":"Hsieh","year":"2026","journal-title":"Mol. Med. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/ecosalplus.esp-0010-2014","article-title":"DNA Topoisomerases","volume":"6","author":"Bush","year":"2015","journal-title":"EcoSal Plus"},{"key":"ref_43","first-page":"e113104","article-title":"RNase H2 degrades toxic RNA:DNA hybrids behind stalled forks to promote replication restart","volume":"42","author":"Kemiha","year":"2023","journal-title":"Embo J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/cmdc.202000391","article-title":"Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy","volume":"15","author":"Yusoh","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00018-019-03299-8","article-title":"Targeting DNA repair in cancer: Current state and novel approaches","volume":"77","author":"Klinakis","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.gendis.2023.02.014","article-title":"Mechanism of PARP inhibitor resistance and potential overcoming strategies","volume":"11","author":"Fu","year":"2024","journal-title":"Genes Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1038\/s41467-023-39332-5","article-title":"ATR kinase supports normal proliferation in the early S phase by preventing replication resource exhaustion","volume":"14","author":"Menolfi","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/PPO.0000000000000561","article-title":"DNA Damage Repair Inhibitors\u2014Combination Therapies","volume":"27","author":"Smith","year":"2021","journal-title":"Cancer J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(03)00048-5","article-title":"Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A","volume":"3","author":"Falck","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1128\/MCB.26.8.3319-3326.2006","article-title":"Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase","volume":"26","author":"Petermann","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ncb1212","article-title":"The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair","volume":"7","author":"Hansen","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","article-title":"The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition","volume":"25","author":"Parmar","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1158\/1078-0432.CCR-21-1279","article-title":"Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors","volume":"27","author":"Do","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/s41467-024-47215-6","article-title":"The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: A phase 2 trial","volume":"15","author":"Giudice","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-20-0219","article-title":"A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer","volume":"26","author":"Oza","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"key":"ref_61","unstructured":"(2026, June 27). EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women with Ovarian Cancer Who Have Progressed During PARP Inhibition, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03579316."},{"key":"ref_62","unstructured":"(2026, June 27). A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (DENALI\/ZN-c3-005\/GOG-3066), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05128825."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","article-title":"ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors","volume":"131","author":"Smith","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Huang, Y., Fan, Y., Zhao, Z., Zhang, X., Tucker, K., Staley, A., Suo, H., Sun, W., Shen, X., and Deng, B. (2023). Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202306.2054.v1"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.celrep.2014.11.044","article-title":"Cdk1 restrains NHEJ through phosphorylation of XRCC4-like factor Xlf1","volume":"9","author":"Hentges","year":"2014","journal-title":"Cell Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/embor.2012.58","article-title":"CDK targeting of NBS1 promotes DNA-end resection, replication restart and homologous recombination","volume":"13","author":"Falck","year":"2012","journal-title":"EMBO Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molcel.2009.06.036","article-title":"Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage","volume":"35","author":"Neil","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/s41467-017-02146-3","article-title":"Cell cycle-dependent phosphorylation regulates RECQL4 pathway choice and ubiquitination in DNA double-strand break repair","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.1093\/nar\/gkw622","article-title":"Phosphorylation of Ku70 subunit by cell cycle kinases modulates the replication related function of Ku heterodimer","volume":"44","author":"Mukherjee","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"13072","DOI":"10.18632\/oncotarget.3865","article-title":"Wee1 is required to sustain ATR\/Chk1 signaling upon replicative stress","volume":"6","author":"Saini","year":"2015","journal-title":"Oncotarget"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0955-0674(96)80080-9","article-title":"Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control","volume":"8","author":"Lew","year":"1996","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.molcel.2004.07.015","article-title":"Polo-like Kinase-1 Controls Recovery from a G2 DNA Damage-Induced Arrest in Mammalian Cells","volume":"15","author":"Medema","year":"2004","journal-title":"Mol. Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s44318-025-00400-9","article-title":"PLK1 inhibition delays mitotic entry revealing changes to the phosphoproteome of mammalian cells early in division","volume":"44","author":"Gobran","year":"2025","journal-title":"EMBO J."},{"key":"ref_74","first-page":"10724","article-title":"PLK1 targets CtIP to promote microhomology-mediated end joining","volume":"46","author":"Wang","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kalous, J., and Aleshkina, D. (2023). Multiple Roles of PLK1 in Mitosis and Meiosis. Cells, 12.","DOI":"10.3390\/cells12010187"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41419-024-06894-1","article-title":"Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas","volume":"15","author":"Chiappa","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.2015.62.1474","article-title":"Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l\u2019Etude des Cancers de l\u2019Ovaire Study","volume":"34","author":"Selle","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/9\/1135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:22:20Z","timestamp":1789791740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/9\/1135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":77,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["genes17091135"],"URL":"https:\/\/doi.org\/10.3390\/genes17091135","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}